论文部分内容阅读
目的比较卡培他滨联合奥沙利铂与替加氟联合奥沙利铂辅助治疗食管鳞癌的生存率。方法对郑州大学附属肿瘤医院2008年1月—20l1年12月应用卡培他滨联合奥沙利铂45例患者与替加氟联合奥沙利铂辅助治疗48例食管鳞癌患者的生存率进行回顾性对比分析。结果卡培他滨联合奥沙利铂组1年生存率95.6%,3年生存率79.6%,替加氟联合奥沙利铂组1年生存率93.7%,3年生存率77.0%,两组患者整体生存率无统计学差异,COX回归模型分析显示年龄和分期是生存率的影响因素。结论卡培他滨联合奥沙利铂与替加氟联合奥沙利铂辅助治疗食管鳞癌生存率无明显差异。
Objective To compare the survival rates of capecitabine combined with oxaliplatin and tegafur plus oxaliplatin in the treatment of esophageal squamous cell carcinoma. Methods The survival rate of 48 patients with esophageal squamous cell carcinoma treated with capecitabine combined with oxaliplatin and tegafur plus oxaliplatin adjuvant in January 2008 -20l1 in Cancer Hospital of Zhengzhou University Retrospective comparative analysis. Results The 1-year survival rate and the 3-year survival rate were 95.6% and 79.6% in capecitabine plus oxaliplatin group, respectively. The 1-year survival rate was 93.7% in tegafur combined with oxaliplatin group and 77.0% in 3-year survival rate. The overall survival rate of patients was no significant difference, COX regression model analysis showed that age and stage are the influencing factors of survival rate. Conclusion Capecitabine combined with oxaliplatin and tegafur plus oxaliplatin adjuvant treatment of esophageal squamous cell carcinoma no significant difference in survival.